• BIA Blog

CEO Update | Monday 22 October

New explainer videos, new R+D tax guide, Commons’ Select committee on AMR and new Scientist.com deal It’s great to celebrate and explain our sector. Last week we launched our Celebrating UK Bioscience videos and re-vamped our Strategic Technologies webpage with fantastic new content. We generated just under half a million unique impressions on Twitter in 3 days, and I’d like you to share these resources with your network to drive better understanding of our sector and what it does.  

Life Sciences Industrial Strategy & Sector Deal Newsletter | October 2018

Welcome to the October edition of the Life Sciences Industrial Strategy & Sector Deal Newsletter. Here you will find an update on how we are progressing with the implementation of phase 1 of the Life Sciences Sector Deal as well as our upcoming priorities and engagement opportunities.

CEO Update | Monday 15 October 2018

We’re at the beginning of a  key week for the BIA as voting closes for our Board elections, and Thursday sees our flagship conference, the Bioscience Forum, along with our AGM and Autumn reception.

Video of the week | The immortal cells of Henrietta Lacks

In order to test medicines, study disease and unravel the workings of human cells, scientists need material to work with. To produce results which are consistent, scientists need the cells they work with to stay same each generation - in other words, they must all be clones. Cells harvested from a tumor belonging to a woman named Henrietta Lacks proved to be the key to this problem. These cells are able to produce faithful copies of themselves and have done so since 1951. Known as HeLa cells, they have been instrumental in producing everything from over-the-counter drugs, to unlocking the secrets of human DNA.

Guest Blog | RPC LLP | Risk management and regulation - an opportunity for life sciences innovators?

  Compliance, regulation and red tape can be burdensome for manufacturers, but should they be viewed more positively? Risk management has the potential to add value and longevity to a product – and to offer an opportunity for growth. Here are reasons why investing in risk management should be a guiding principle for the entire product development cycle, from the initial concept right through to marketing and post-market surveillance:

BIA calls for a strong industry voice in UKRI funding decisions

It’s a busy time in research and innovation policy. We are in the midst of an historic reorganisation of the funding infrastructure with the creation of UK Research & Innovation (UKRI) and a 20% increase in public investment. With critically-needed money now available, attention is turning to how it can be best spent. With this in mind, the House of Commons Science and Technology Select Committee is running an inquiry on the balance of research funding.

CEO Update Monday 8 October 2018

It was fantastic to see Greg Winter, serial entrepreneur and founder of BIA member Bicycle Therapeutics jointly awarded the Nobel Prize for Chemistry. His ground-breaking work humanising antibodies led to the production of Humira, the best selling prescription drug last year. The Nobel Prize in Physiology or Medicine was awarded jointly to James P. Allison and Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation. The two breakthroughs together provide the scientific underpinning for the fantastic work our sector has done to translate this science into practical therapies for patients.

Video of the week | Why do you need to get a flu vaccine every year?

Every year, the race is on to produce the next flu vaccine. But why do we need to get a new shot every year when just a shot and a booster as a child protects us from other diseases like the whooping cough or the measles? Something about the flu must be different.